A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 814 participants.

Also called NCT03018938

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 814 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03018938
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03018938. Randomized; no masking; primary purpose treatment. Start 2017-02-06 (actual); primary completion 2019-02-19 (actual). Results posted on 2020-03-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus
Acronym
CLASSIC
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin Analog Mid Mixture
Intervention (Drug)
Basal Insulin Analog
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03018938
Content hash
35e7b560963296317958636c0ff5a6a3b59ed488c18cd1d0b758f34f2311fac2